Effects of continuous positive airway pressure therapy on systemic inflammation in obstructive sleep apnea: A meta-analysis

Xie, Xiaomei; Pan, Lei; Du, Caigan; Guo, Yueyue

doi:10.1016/j.sleep.2013.07.006

Cited by 126 publications

(85 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Much evidence demonstrates that treatment of OSA, including CPAP or surgery, can reduce inflammation and oxidative stress. 7,44,45 A recent meta-analysis of 35 studies involving 1,985 patients with OSA also confirmed that CPAP therapy could partially suppress systemic inflammation and there are differences among the various inflammatory markers such as CRP, IL-6, IL-8, and TNF-α. 7 However, CPAP is underused as a therapy for OSA even though investigators have demonstrated that CPAP may reduce the risk of atrial fibrillation or stroke.…”

Section: 9-11mentioning

confidence: 89%

“…7,44,45 A recent meta-analysis of 35 studies involving 1,985 patients with OSA also confirmed that CPAP therapy could partially suppress systemic inflammation and there are differences among the various inflammatory markers such as CRP, IL-6, IL-8, and TNF-α. 7 However, CPAP is underused as a therapy for OSA even though investigators have demonstrated that CPAP may reduce the risk of atrial fibrillation or stroke. 46 Results of the current study also revealed that CPAP may reduce the risk of RA in patients with OSA depending on the extent of decrease of inflammatory mediators and oxidative stress.…”

Section: 9-11mentioning

confidence: 89%

“…4 Therefore, OSA is thought to be a systemic inflammatory disease, and treatment of OSA, such as continuous positive airway pressure (CPAP), could suppress the systemic inflammation in patients with OSA. [5][6][7] Autoimmune diseases are multifactorial, resulting from dysregulation of the immune system and autoimmune-mediated damage to normal tissue. Triggering factors in a host predisposed by genetic background may result in an aberrant immunological response.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Management and Risk Reduction of Rheumatoid Arthritis in Individuals with Obstructive Sleep Apnea: A Nationwide Population-Based Study in Taiwan

Chen

Chang

et al. 2016

Sleep

View full text Add to dashboard Cite

Section: 9-11mentioning

confidence: 89%

Section: 9-11mentioning

confidence: 89%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Management and Risk Reduction of Rheumatoid Arthritis in Individuals with Obstructive Sleep Apnea: A Nationwide Population-Based Study in Taiwan

Chen

Chang

et al. 2016

Sleep

View full text Add to dashboard Cite

“…CRP levels further declined after 6 mo of PAP treatment. Furthermore, Xie et al [76] also showed a significant decrease on CRP levels, with better benefits with therapy duration of ≥ 3 mo and more adequate compliance (≥ 4 h/night). A previous metaanalysis showed PAP therapy to significantly reduce CRP factors such as obesity, other CVDs and medications.…”

Section: Effect Of Positive Airway Pressure Therapy On Levels Of Crpmentioning

confidence: 92%

Obstructive sleep apnea syndrome and cardiovascular disease: The influence of C-reactive protein

Bouloukaki¹,

Mermigkis²,

Kallergis³

et al. 2015

WJEM

View full text Add to dashboard Cite

Obstructive sleep apnea syndrome (OSAS) is a common medical condition, associated with atherosclerosis and cardiovascular disease (CVD). The underlying pathophysiologic mechanisms of this association have not been completely understood and may be multifactorial in origin. A number of studies suggest that inflammatory processes have emerged critical in the pathogenesis of CVD in OSAS. A range of circulating inflammatory molecules has been identified and measured, with a view to assess inflammation and predict vascular damage risk, such as plasma cytokines, adhesion molecules, and C-reactive protein (CRP). CRP is a relevant marker worthy of further study, because not only is elevated in patients with OSAS, but also is rapidly becoming a risk factor for cardiac disease. Furthermore, in selected OSAS patients, aggressive treatment of the disorder may lead to retarding or even improvement of CVD progression. However, still there is a debate on the true correlation between CRP and OSAS, as well as the clinical effect of any reduction after OSAS treatment. Further research is required to define those OSAS patients who will have a considerable reduction with treatment, as well as to understand the significance of the interaction between cardiovascular risk factor and CRP reduction in patients with OSAS.

show abstract

“…In the meantime, several studies have demonstrated the clinical benefit of continuous positive airway pressure (CPAP) therapy for patients with OSA in relation to atherosclerosis-related parameters such as inflammatory markers, lipid profile, and blood pressure. [8][9][10] However, reported CPAP therapy usage frequency ranges from 29% to 85%, suggesting that positive adherence has not yet been achieved. 11 Therefore, the development of a simple predictive modality for patients with OSA who require CPAP therapy is needed.…”

Section: Scientific Investigations Circulating Anti-coatomer Protein mentioning

confidence: 99%

Circulating Anti-Coatomer Protein Complex Subunit Epsilon (COPE) Autoantibodies as a Potential Biomarker for Cardiovascular and Cerebrovascular Events in Patients with Obstructive Sleep Apnea

Matsumura

Terada

Kinoshita

et al. 2017

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

Study Objectives: Although moderate to severe obstructive sleep apnea (OSA) is an independent risk factor for severe arteriosclerotic diseases such as cardiovascular disease (CVD) and stroke, the development of atherosclerosis-related diseases cannot yet be predicted in patients with OSA. In a pilot study, we identified autoantibodies against the coatomer protein complex, subunit epsilon [circulating anti-coatomer protein complex subunit epsilon autoantibody (COPE-Ab)], a cytosolic complex that mediates protein transport in the Golgi compartment, as a potential novel biomarker of atherosclerosis. This study aimed to evaluate whether COPE-Ab levels had an association with cardiovascular and cerebrovascular events in patients with OSA. Methods: Eighty-two adult patients with a diagnosis of OSA via polysomnography and 64 healthy donors were studied. Serum COPE-Ab levels were measured using an amplified luminescence proximity homogeneous assay. Then, clinical factors related to atherosclerosis were evaluated with respect to COPE-Ab levels. Results: Significant differences in COPE-Ab levels were observed in terms of OSA severity. COPE-Ab levels were significantly higher in patients with OSA and also CVD and/or stroke, hypertension, and a high body mass index. Univariate and multivariate logistic regression analyses of patients with OSA identified elevated COPE-Ab level as a significant predictor of CVD and/or stroke. Conclusions: An elevated COPE-Ab level may be a potential predictor of the risks of cardiovascular and cerebrovascular events in patients with OSA. Therefore, patients with higher COPE-Ab levels may require more careful and intensive treatment. Commentary: A commentary on this article appears in this issue on page 361.

show abstract

Effects of continuous positive airway pressure therapy on systemic inflammation in obstructive sleep apnea: A meta-analysis

Cited by 126 publications

References 56 publications

Management and Risk Reduction of Rheumatoid Arthritis in Individuals with Obstructive Sleep Apnea: A Nationwide Population-Based Study in Taiwan

Management and Risk Reduction of Rheumatoid Arthritis in Individuals with Obstructive Sleep Apnea: A Nationwide Population-Based Study in Taiwan

Obstructive sleep apnea syndrome and cardiovascular disease: The influence of C-reactive protein

Circulating Anti-Coatomer Protein Complex Subunit Epsilon (COPE) Autoantibodies as a Potential Biomarker for Cardiovascular and Cerebrovascular Events in Patients with Obstructive Sleep Apnea

Contact Info

Product

Resources

About